Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Balcells, 2020
 
NCT04375098
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedlow
28/30 inconclusive
  • inconclusive 33 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias
ConPlas-19, 2020
 
NCT04345523
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
38/43 inconclusive
    Gharbharan et al., 2020
     
    NCT04342182
    RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
    43/43 inconclusive
    • inconclusive 5 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias

    COVID-19 mild to moderate meta-analysis

    PLACID, 2020
     
    CTRI/2020/04/024775
    RCTconvalescent plasma treatmentstandard of careCOVID-19 mild to moderatehigh
    235/229 suggested
    • inconclusive 7 % increase in death or transfer to ICU (PE) but with a low degree of certainty due to high risk of bias
    • suggested 20 % increase in PCR-negative conversion (7-day) but with a low degree of certainty due to high risk of bias

    COVID-19 severe or critically meta-analysis

    AlQahtani, 2020
     
    NCT04356534
    RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
    20/20 inconclusive
    • inconclusive 33 % decrease in ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
    Li, 2015
     
    ChiCTR2000029757
    RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
    52/51 inconclusive
    • inconclusive 40 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).